Last reviewed · How we verify
Extensive stage primary small cell carcinoma of lung
Approved treatments
- Imfinzi · AstraZeneca
Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells. - Imfinzi · University Medical Center Groningen
- Tecentriq · Roche
Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Extensive stage primary small cell carcinoma of lung patent landscape — cliff calendar, originator estates, attackable patents
- Extensive stage primary small cell carcinoma of lung treatment landscape brief
- Extensive stage primary small cell carcinoma of lung treatment updates RSS
Frequently asked questions about Extensive stage primary small cell carcinoma of lung
What drugs treat Extensive stage primary small cell carcinoma of lung?
Tracked treatments include Imfinzi, Tecentriq.
What is the treatment for Extensive stage primary small cell carcinoma of lung?
Standard treatment for Extensive stage primary small cell carcinoma of lung includes Imfinzi, Tecentriq. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Extensive stage primary small cell carcinoma of lung patent cliff · Extensive stage primary small cell carcinoma of lung CI report
- Treatment: Imfinzi · AstraZeneca
- Treatment: Imfinzi · University Medical Center Groningen
- Treatment: Tecentriq · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing